TEM
A trial result with real-world bite
Tempus AI took the stage at the American College of Cardiology’s annual meeting with something investors actually like to hear: the ALERT trial met its endpoint. In plain English, the company’s EHR-based alerts did a better job than usual care at nudging clinicians to spot undertreated aortic stenosis and mitral regurgitation.
Why the stock cares
This wasn’t just a nerdy slide-deck victory lap. Tempus said the alerts were linked to 40% more valve procedures and 27% more heart team evaluations within 90 days. That’s the kind of data that helps the company argue its platform can move from “interesting software” to “actual clinical workflow muscle.”
The bigger sell
The trial covered 765 clinicians and 2,016 echos, which gives the results a bit more weight than your average conference cameo. Tempus is pitching a device-agnostic, EHR-connected approach to close care gaps, which is basically the healthcare version of a GPS saying, “Uh, hey, you missed your exit.”
Big picture
If Tempus can keep showing that its data tools change doctor behavior—not just crunch numbers—it strengthens the case for broader adoption and future revenue. Investors are betting on the company becoming a platform, not just a diagnostics name, and this kind of readout is how that story gets written.